Allergy Therapeutics provided a regulatory update following its recent end-of-Phase II meeting with the FDA and the Paul Ehrlich Institut (PEI) for PQ Grass. The company indicated that the PQ Grass Phase III study will now start in FY 2020, a year later than expected, to ensure that the best possible protocol is agreed. Meanwhile, AGY continues to trade in line with expectations and gain market share, implying that physicians have not changed their prescribing habits despite the Phase III PQ ....